Drug
Avoralstat
Avoralstat: highest development phase Phase 3, developed by BioCryst Pharmaceuticals. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- BioCryst Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| avoralstat NCT02670720 | Phase 3 | Hereditary Angioedema |
| avoralstat NCT07228559 | Phase 1 | Diabetic Macular Edema (DME) |
Latest
No recent events.
Follow Avoralstat on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.